Oklahoma City, Oklahoma, April 30, 2020 – Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Matthew Delaney to Vice President of Business Development and Marketing. Mr. Delaney will serve on the Senior Leadership Team and report to Dr. Jesse McCool, Chief Executive Officer for Cytovance Biologics.
“We are delighted to welcome Matt onto the Senior Leadership Team in Oklahoma City. His two decades of BD and marketing experience combined with a deep knowledge of the CDMO markets will help accelerate Cytovance’s expansion into the rapidly growing biologics and gene therapy sectors,” stated Dr. Jesse McCool, CEO of Cytovance Biologics. “Matt shows up with integrity, high energy, and a clear commitment to understanding and exceeding the needs of our customers. I’m very pleased to have him on my team.”
In this role, Mr. Delaney will be responsible for the leadership of the Cytovance Biologics sales and marketing teams, developing new business opportunities and creating customized solutions to meet unique customer requirements. Mr. Delaney will lead the continued acceleration of Cytovance’s revenue growth through the expansion of the company’s R&D and CGMP mammalian and microbial pipelines along with its recent entry into the gene therapy space.
Mr. Frank Sun, Chairman of the Board of Cytovance stated, “Mr. Delaney has an impressive background in developing new business in the global CDMO market and offers significant experience selling plasmid DNA and other gene therapy services. His background and experience will help Cytovance take advantage of the booming biotech R&D demand and become a global leader in biologics and gene therapy CDMO services.”
Prior to joining Cytovance in August 2019, Mr. Delaney earned 20 years of experience where he served as President of Datatrak International – a Software as a Service (SaaS Model) solution provider, the Vice President of Pharm-Olam International – a CRO, and roles with Nitto Avecia – a CDMO R&D and CGMP biotech company.
About Cytovance® Biologics
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule active pharmaceutical ingredients (APIs) from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to its clinical and commercial cGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical chemistry manufacturing and controls (CMC) activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.
Cytovance offers deep industry expertise and unique customized services for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical development to commercial production, for both mammalian and microbial. Further information can be found at www.cytovance.com.